How much revenue does ShanXi C&Y Pharmaceutical Group make?

ShanXi C&Y Pharmaceutical Group reported 870.79 million CNY in revenue for fiscal year 2025, up 2.9% from 846.61 million CNY in fiscal year 2024. In Q1 2026 revenue was 173.80 million CNY.

What is ShanXi C&Y Pharmaceutical Group's largest business segment?

Medicine, with 818.46 million CNY or 97% of segment revenue in fiscal year 2024. Next: Services (2%) and Health Food (1%).

Where does ShanXi C&Y Pharmaceutical Group make most of its revenue?

East China: 43% of revenue by region in fiscal year 2024, followed by Central China (15%).

What companies are similar to ShanXi C&Y Pharmaceutical Group?

Listed companies of a similar size in the same industry (multi-therapeutic drug manufacturing) include Shanghai Fudan Forward S&T Co., Ltd (600624.SS), Anhui Fengyuan Pharmaceutical Co., Ltd. (000153.SZ), Honz Pharmaceutical Co., Ltd. (300086.SZ), Hanshang Group Co., Ltd. (600774.SS).

ShanXi C&Y Pharmaceutical Group Co.,LTD. (300254.SZ) Stock

About ShanXi C&Y Pharmaceutical Group Co.,LTD.

ShanXi C&Y Pharmaceutical Group Co.,LTD. engages in the research, development, production, and sale of medicine and health food products. It provides anti-infective drugs, anti-allergic drugs, smoking cessation drugs, pediatric drugs, respiratory system drugs, urinary system drugs, kidney disease drugs, children's drugs, cardiovascular and cerebrovascular drugs, nephropathy drugs, anti-depressants...

At a glance

ShanXi C&Y Pharmaceutical Group reported revenue of 870.79 million CNY for fiscal year 2025, up 2.9% from fiscal year 2024, and net income of 24.85 million CNY. In Q1 2026 (the quarter ended March 31, 2026) revenue was 173.80 million CNY, down 4.4% from a year before. Its largest business segment, Medicine, brought in 97% of segment revenue in fiscal year 2024; East China was the largest region with 43%.

Figures from company filings; latest fiscal year ended December 31, 2025.

No profile data available.

Disclaimer: This analysis is for informational and educational purposes only and does not constitute financial, investment, tax, or legal advice. Data may be incomplete, delayed, or contain inaccuracies. Consult with a qualified financial advisor before making any investment decisions.